...
apvo-img

Aptevo Therapeutics Inc, Common Stock

APVO

NAQ

$4.215

+$0.13

(3.18%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
336.94K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
5.07
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.08 L
$399.6 H
$4.215

About Aptevo Therapeutics Inc, Common Stock

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAPVOSectorS&P500
1-Week Return-57.84%-2.28%-0.57%
1-Month Return-54.47%-3.98%1.2%
3-Month Return-68.85%-9.71%7.56%
6-Month Return-85.85%-3.39%11.44%
1-Year Return-98.56%3.69%28.47%
3-Year Return-99.97%3.78%29.51%
5-Year Return-99.97%39.76%90.64%
10-Year Return-100%106.88%203.73%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue32.42M4.31M12.29M3.11M-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":13.29,"profit":true},{"date":"2021-12-31","value":37.91,"profit":true},{"date":"2022-12-31","value":9.6,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue19.93M17.85M18.99M901.00K567.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.59,"profit":true},{"date":"2021-12-31","value":95.32,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":2.85,"profit":true}]
Gross Profit12.50M(13.54M)12.29M2.21M(567.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-108.37,"profit":false},{"date":"2021-12-31","value":98.36,"profit":true},{"date":"2022-12-31","value":17.71,"profit":true},{"date":"2023-12-31","value":-4.54,"profit":false}]
Gross Margin38.54%(314.30%)100.00%71.07%-[{"date":"2019-12-31","value":38.54,"profit":true},{"date":"2020-12-31","value":-314.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.07,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses40.96M31.80M33.69M31.75M28.88M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.64,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":77.52,"profit":true},{"date":"2023-12-31","value":70.5,"profit":true}]
Operating Income(40.96M)(27.49M)(21.40M)(28.64M)(28.88M)[{"date":"2019-12-31","value":-4096200000,"profit":false},{"date":"2020-12-31","value":-2749400000,"profit":false},{"date":"2021-12-31","value":-2140000000,"profit":false},{"date":"2022-12-31","value":-2864100000,"profit":false},{"date":"2023-12-31","value":-2887800000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(43.06M)(30.92M)(29.41M)7.01M(18.65M)[{"date":"2019-12-31","value":-613.97,"profit":false},{"date":"2020-12-31","value":-440.88,"profit":false},{"date":"2021-12-31","value":-419.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-265.9,"profit":false}]
Income Taxes(2.62M)(12.47M)(2.10M)(35.66M)(1.24M)[{"date":"2019-12-31","value":-261600000,"profit":false},{"date":"2020-12-31","value":-1247500000,"profit":false},{"date":"2021-12-31","value":-209500000,"profit":false},{"date":"2022-12-31","value":-3565500000,"profit":false},{"date":"2023-12-31","value":-123900000,"profit":false}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(44.70M)(30.92M)(29.41M)7.01M(17.62M)[{"date":"2019-12-31","value":-637.27,"profit":false},{"date":"2020-12-31","value":-440.88,"profit":false},{"date":"2021-12-31","value":-419.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-251.17,"profit":false}]
Income From Discontinued Operations4.25M13.17M951.00K1.01M-[{"date":"2019-12-31","value":32.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.22,"profit":true},{"date":"2022-12-31","value":7.69,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(40.45M)(18.45M)(27.31M)42.67M(17.41M)[{"date":"2019-12-31","value":-94.79,"profit":false},{"date":"2020-12-31","value":-43.24,"profit":false},{"date":"2021-12-31","value":-64.01,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-40.8,"profit":false}]
EPS (Diluted)(15.96)(8.96)(6.09)1.58(7.50)[{"date":"2019-12-31","value":-1010.13,"profit":false},{"date":"2020-12-31","value":-567.09,"profit":false},{"date":"2021-12-31","value":-385.44,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-474.68,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

APVO
Cash Ratio 1.32
Current Ratio 1.70

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

APVO
ROA (LTM) -72.75%
ROE (LTM) -250.96%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

APVO
Debt Ratio Lower is generally better. Negative is bad. 0.71
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.29

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

APVO
Trailing PE NM
Forward PE 3.94
P/S (TTM) 1.61
P/B 0.64
Price/FCF NM
EV/R 0.12
EV/Ebitda 0.39
PEG NM

FAQs

What is Aptevo Therapeutics Inc share price today?

Aptevo Therapeutics Inc (APVO) share price today is $4.215

Can Indians buy Aptevo Therapeutics Inc shares?

Yes, Indians can buy shares of Aptevo Therapeutics Inc (APVO) on Vested. To buy Aptevo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aptevo Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Aptevo Therapeutics Inc (APVO) via the Vested app. You can start investing in Aptevo Therapeutics Inc (APVO) with a minimum investment of $1.

How to invest in Aptevo Therapeutics Inc shares from India?

You can invest in shares of Aptevo Therapeutics Inc (APVO) via Vested in three simple steps:

  • Click on Sign Up or Invest in APVO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aptevo Therapeutics Inc shares
What is Aptevo Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Aptevo Therapeutics Inc (APVO) is $399.6. The 52-week low price of Aptevo Therapeutics Inc (APVO) is $4.08.

What is Aptevo Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Aptevo Therapeutics Inc (APVO) is

What is Aptevo Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aptevo Therapeutics Inc (APVO) is 0.64

What is Aptevo Therapeutics Inc dividend yield?

The dividend yield of Aptevo Therapeutics Inc (APVO) is 0.00%

What is the Market Cap of Aptevo Therapeutics Inc?

The market capitalization of Aptevo Therapeutics Inc (APVO) is $5.01M

What is Aptevo Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Aptevo Therapeutics Inc is APVO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top